Access the world's leading financial data and tools

Subscribe for $2
Overview
Profile

Vericel stock

VCEL
US92346J1088
A12FU4

Price

56.38
Today +/-
+1.38
Today %
+2.58 %

Vericel stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Vericel stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Vericel stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Vericel stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Vericel's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Vericel Stock Price History

DateVericel Price
12/20/202456.38 undefined
12/19/202454.95 undefined
12/18/202456.25 undefined
12/17/202456.69 undefined
12/16/202456.46 undefined
12/13/202457.47 undefined
12/12/202457.01 undefined
12/11/202457.92 undefined
12/10/202457.56 undefined
12/9/202456.36 undefined
12/6/202456.37 undefined
12/5/202456.52 undefined
12/4/202458.15 undefined
12/3/202458.24 undefined
12/2/202458.74 undefined
11/29/202458.14 undefined
11/27/202457.76 undefined
11/26/202458.75 undefined
11/25/202458.57 undefined
11/22/202459.11 undefined
11/21/202456.71 undefined

Vericel Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Vericel, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Vericel from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Vericel’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Vericel. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Vericel’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Vericel’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Vericel’s growth potential.

Vericel Revenue, EBIT and net profit per share

DateVericel RevenueVericel EBITVericel Net Income
2029e730.47 M undefined214.31 M undefined141.98 M undefined
2028e581.11 M undefined113.82 M undefined85.84 M undefined
2027e476.31 M undefined81.87 M undefined64.28 M undefined
2026e371.88 M undefined49.79 M undefined42.51 M undefined
2025e299.6 M undefined24.52 M undefined23.45 M undefined
2024e244.56 M undefined2.92 M undefined6.23 M undefined
2023197.52 M undefined-6.46 M undefined-3.18 M undefined
2022164.4 M undefined-17.1 M undefined-16.7 M undefined
2021156.2 M undefined-7.9 M undefined-7.5 M undefined
2020124.2 M undefined2.4 M undefined2.9 M undefined
2019117.9 M undefined-11.3 M undefined-9.7 M undefined
201890.9 M undefined-3.9 M undefined-8.1 M undefined
201763.9 M undefined-14.9 M undefined-17.3 M undefined
201654.4 M undefined-16.6 M undefined-27.1 M undefined
201551.2 M undefined-16.7 M undefined-23.1 M undefined
201428.8 M undefined-18.9 M undefined-25.9 M undefined
20130 undefined-21 M undefined-21 M undefined
20120 undefined-33.8 M undefined-33.5 M undefined
20110 undefined-29 M undefined-19.7 M undefined
2010100,000 undefined-17.8 M undefined-14.6 M undefined
2009200,000 undefined-16.2 M undefined-16.1 M undefined
2008500,000 undefined-21.2 M undefined-15.5 M undefined
2007700,000 undefined-19.5 M undefined-17.6 M undefined
2006900,000 undefined-17.7 M undefined-16.5 M undefined
2005900,000 undefined-12.4 M undefined-11.8 M undefined
20041.3 M undefined-10.7 M undefined-10.5 M undefined

Vericel Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
000001000100010000000002851546390117124156164197244299371476581730
------------------------82.145.8816.6742.8630.005.9825.815.1320.1223.8622.5424.0828.3022.0625.65
-----13,500.00---13,500.00---100.00---------50.0047.0648.1552.3864.4468.3867.7467.9566.4668.5355.3345.1536.3928.3623.2418.49
0000000000000100000000014242633588084106109135000000
-1-1-2-6-5-9-14-21-11-9-5-7-9-10-11-16-17-15-16-14-19-33-21-25-23-27-17-8-92-7-16-3623426485141
--100.00200.00-16.6780.0055.5650.00-47.62-18.18-44.4440.0028.5711.1110.0045.456.25-11.766.67-12.5035.7173.68-36.3619.05-8.0017.39-37.04-52.9412.50-122.22-450.00128.57-81.25-300.00283.3382.6152.3832.8165.88
0.10.10.1000.10.10.10.10.10.20.30.30.50.60.70.70.80.91.21.92.1311.623.823.133.440.244.247.346.547.147.59000000
---------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Vericel Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Vericel is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
                                                           
11.1111711.27.512.710.79.610.516.932.44328.322.51719.131.25.513.68.130.314.62326.982.969.775.8103.4119.5109.56
0.10.10.20.20.10.20.10.10.40.20.20.10.100.1000008.210.917.118.323.532.234.537.446.558.36
000000000000000000000000000000
00001.100.71.40.80.40.10000000001.91.43.53.83.66.89.413.41613.09
0.10.40.10.30.30.20.20.20.20.30.40.51.81.60.70.40.40.60.40.410.51.21.62.833.94.24.824.63
11.311.517.311.7913.111.711.311.917.833.143.630.224.117.819.531.66.1148.541.427.444.850.6112.8111.7123.6158.4186.8205.63
1.31.210.70.50.30.20.20.30.30.61.12.72.21.511.11.61.20.72.943.94.15.932.257.75957.4115.1
00000000000000000000000009.224.125.72025.28
000000000000000000000000000000
000000000000000000003.22.90000007.56.88
000000000000000000000000000000
00000000000.10.100000000000000.10.20.51.30.77
1.31.210.70.50.30.20.20.30.30.71.22.72.21.511.11.61.20.76.16.93.94.15.941.58285.286.2148.03
12.612.718.312.49.513.411.911.512.218.133.844.832.926.319.320.532.77.715.29.247.534.348.754.7118.7153.2205.6243.6273353.66
                                                           
28.534.558.169.478.992.496.8104.6115131.5158.7184.5188203.2205.3217.9225.1228.9284.8291.7343.4349.3368.1383471.2489.7510.1553.9593.2629.23
-0.2-0.2-0.2000000000000000000000000000
-17.1-27-41.3-58.9-70.3-79.9-85.9-93.8-103.4-113.9-125.7-142.2-159.7-179.9-188.5-203.1-222.2-241.8-275.3-287.8-307.7-324-343.4-360.5-368.9-378.7-375.8-383.3-400-403.18
03.500.30000000000000000-0.1000000-0.2-1-0.1
000000000000000000000000000000
11.210.816.610.88.612.510.910.811.617.63342.328.323.316.814.82.9-12.99.53.935.625.324.722.5102.3111134.3170.4192.2225.95
0.31.21.51.30.30.10.30.40.30.20.20.40.50.30.91.72.12.22.82.45.87.66.55.67.16.36.8916.922.35
0.10.10.10.20.80.90.80.40.30.40.72.22.51.30.40.71.61.80.80.93.93.44.55.66.913.415.71720.523.4
0.20.10000000000000.532616.6222.11.111.60.800000
000000000000000000000000000000
3002001001000000000040040050020020000000800400000000
0.91.61.71.61.111.10.80.60.60.92.63.422.35.629.920.65.65.311.812.112.813.214.819.722.52637.445.75
0.40.20.10000000001.10.80.30.100000.10.19.416.900.10.1000.1
000000000000000000000000000000
00000000000000000000001.72.11.722.248.847.143.381.86
0.40.20.10000000001.10.80.30.100000.10.111.1191.722.348.947.143.381.96
1.31.81.81.61.111.10.80.60.60.92.64.52.82.65.729.920.65.65.311.912.223.932.216.54271.473.180.7127.7
12.512.618.412.49.713.51211.612.218.233.944.932.826.119.420.532.87.715.19.247.537.548.654.7118.8153205.7243.5272.9353.66
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Vericel provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Vericel's financial health and stability.

Assets

Vericel's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Vericel must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Vericel after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Vericel's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (k)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (k)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
19931994199519961997199819992000200120022003200420052006200720082009201020102011201220132014201520162017201820192020202120222023
-6-6-5-9-14-17-11-9-5-7-9-10-11-16-17-15-16-14-19-19-29-15-19-16-19-17-8-92-7-16-3
00000000000000000000000111112234
00000000000000000000000000000000
000000-1,00000-1,0000001,0000-1,00001,0001,000000-2,000-1,000-9,000-2,000-3,000-14,000-6,000-6,000-11,000-3,000
000001120010002-12-18-12-3-2597172832747870
00000000000000000000000000200000
00000000000000000000000000000001,000
-5-5-5-9-13-15-11-6-6-8-8-9-11-13-14-19-13-15-9-24-29-19-25-13-19-130-717291735
00000000000000-10000-1000-2-1-1-2-2-2-7-7-27
-1-1-78-1559-1010-100-18-161895-54-100-2-2-1-1-6710-17-3-36-3
00-78-1469-1010-110-17-151996-55000-1000-6413-144-2824
00000000000000000000000000000000
000000000000000000000000106-1700000
9996191071247101627240138172103714490191277561136
99991997124710162724013817210371449029185856913
00030000000000000000000000000-2-2-2
00000000000000000000000000000000
22-38-905-58-216-2-5430-217-258-522-1583-88634-1735
-6.06-6.06-5.38-9.53-13.72-15.87-11.27-7.02-6.42-8.9-9.11-9.69-11.66-14.31-15.89-19.75-13.85-15.21-9.56-25.52-29.82-19.98-26.24-15.78-21.31-14.69-3.09-9.814.9421.1210.097.8
00000000000000000000000000000000

Vericel stock margins

The Vericel margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Vericel. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Vericel.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Vericel's sales revenue. A higher gross margin percentage indicates that the Vericel retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Vericel's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Vericel's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Vericel's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Vericel. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Vericel's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Vericel Margin History

Vericel Gross marginVericel Profit marginVericel EBIT marginVericel Profit margin
2029e68.64 %29.34 %19.44 %
2028e68.64 %19.59 %14.77 %
2027e68.64 %17.19 %13.5 %
2026e68.64 %13.39 %11.43 %
2025e68.64 %8.18 %7.83 %
2024e68.64 %1.19 %2.55 %
202368.64 %-3.27 %-1.61 %
202266.79 %-10.4 %-10.16 %
202167.86 %-5.06 %-4.8 %
202067.79 %1.93 %2.33 %
201968.11 %-9.58 %-8.23 %
201864.58 %-4.29 %-8.91 %
201752.58 %-23.32 %-27.07 %
201647.98 %-30.51 %-49.82 %
201548.24 %-32.62 %-45.12 %
201448.61 %-65.63 %-89.93 %
201368.64 %0 %0 %
201268.64 %0 %0 %
201168.64 %0 %0 %
2010100 %-17,800 %-14,600 %
200950 %-8,100 %-8,050 %
2008100 %-4,240 %-3,100 %
2007100 %-2,785.71 %-2,514.29 %
2006100 %-1,966.67 %-1,833.33 %
200588.89 %-1,377.78 %-1,311.11 %
200476.92 %-823.08 %-807.69 %

Vericel Stock Sales Revenue, EBIT, Earnings per Share

The Vericel earnings per share therefore indicates how much revenue Vericel has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vericel earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vericel's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vericel’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vericel's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vericel Revenue, EBIT and net profit per share

DateVericel Sales per ShareVericel EBIT per shareVericel Earnings per Share
2029e14.8 undefined0 undefined2.88 undefined
2028e11.77 undefined0 undefined1.74 undefined
2027e9.65 undefined0 undefined1.3 undefined
2026e7.53 undefined0 undefined0.86 undefined
2025e6.07 undefined0 undefined0.48 undefined
2024e4.95 undefined0 undefined0.13 undefined
20234.15 undefined-0.14 undefined-0.07 undefined
20223.49 undefined-0.36 undefined-0.35 undefined
20213.36 undefined-0.17 undefined-0.16 undefined
20202.63 undefined0.05 undefined0.06 undefined
20192.67 undefined-0.26 undefined-0.22 undefined
20182.26 undefined-0.1 undefined-0.2 undefined
20171.91 undefined-0.45 undefined-0.52 undefined
20162.35 undefined-0.72 undefined-1.17 undefined
20152.15 undefined-0.7 undefined-0.97 undefined
20142.48 undefined-1.63 undefined-2.23 undefined
20130 undefined-7 undefined-7 undefined
20120 undefined-16.1 undefined-15.95 undefined
20110 undefined-15.26 undefined-10.37 undefined
20100.08 undefined-14.83 undefined-12.17 undefined
20090.22 undefined-18 undefined-17.89 undefined
20080.63 undefined-26.5 undefined-19.38 undefined
20071 undefined-27.86 undefined-25.14 undefined
20061.29 undefined-25.29 undefined-23.57 undefined
20051.5 undefined-20.67 undefined-19.67 undefined
20042.6 undefined-21.4 undefined-21 undefined

Vericel business model

Vericel Corp is a US biotechnology company specializing in the development and commercialization of innovative cell therapies for patients with serious diseases. The company is headquartered in Cambridge, Massachusetts and was founded in 1997. Vericel is one of the most popular companies on Eulerpool.com.

Vericel SWOT Analysis

Strengths

Vericel Corp has a number of strengths that give it a competitive advantage in the market. One of its notable strengths is its innovative and high-quality product portfolio. The company offers advanced cell therapies that have shown significant success in treating various medical conditions. This cutting-edge technology attracts customers and positions Vericel as a leader in the industry. Another strength is Vericel's strong research and development capabilities. The company invests heavily in R&D to continuously improve its existing products and develop new ones. This commitment to innovation allows Vericel to stay ahead of its competitors and offer superior treatments to patients. Additionally, Vericel benefits from a robust distribution network. The company has established collaborations with healthcare providers, hospitals, and other organizations worldwide. This extensive network enables Vericel to reach a large customer base and effectively distribute its products. Lastly, Vericel has a talented team of professionals, including experienced researchers and highly skilled employees. This expertise ensures efficient operations and the ability to adapt to changing market dynamics.

Weaknesses

Despite its strengths, Vericel Corp also faces certain weaknesses. One weakness is its dependence on a limited number of products. While Vericel's existing products are successful, this concentration poses a risk if the market demand for these products declines or if competition intensifies. Another weakness is the regulatory environment surrounding cell therapies. The regulatory requirements for approval and marketing of these therapies can be complex and time-consuming. Vericel needs to navigate this landscape carefully to ensure timely commercialization of its products. Additionally, Vericel's financial performance has been reliant on the success of a few key products. This dependency on a small subset of products introduces financial risk if those products underperform or face challenges in the market. Lastly, Vericel may face challenges in scaling up its manufacturing capabilities to meet increasing demand. The production of cell therapies often requires specialized facilities and processes, which can be costly and resource-intensive.

Opportunities

Vericel Corp has several opportunities that can contribute to its growth and success. Market expansion is an important opportunity as the demand for innovative cell therapies is expected to increase. Vericel can explore new geographic markets, expand its product offerings, and target additional medical conditions that can benefit from its therapies. Furthermore, partnerships and collaborations can open up new avenues for Vericel. Collaborating with research institutions, healthcare providers, and industry leaders can help accelerate R&D efforts, access new technological advancements, and enhance market presence. Another opportunity lies in leveraging digital technologies and data analytics. Vericel can utilize these tools to optimize its operations, enhance customer experience, and gain valuable insights into patient outcomes. This can lead to improved treatments and increased customer loyalty.

Threats

Vericel Corp faces certain threats that could impact its performance and market position. One major threat is intense competition in the cell therapy industry. Numerous companies are vying for market share and actively developing similar therapies. Vericel needs to continuously innovate and differentiate its products to stay ahead of the competition. Another threat is the potential for changes in regulations and reimbursement policies. Policy changes can impact market access, pricing, and profitability. Vericel must closely monitor regulatory developments and adapt its strategy accordingly. Additionally, potential disruptions in the supply chain and manufacturing processes could pose threats. Vericel relies on raw materials, resources, and specialized facilities to produce its therapies. Any disruptions in these areas can lead to delays in product availability and impact customer satisfaction. Lastly, Vericel may face risks associated with unexpected adverse events or side effects related to its therapies. Public concerns, legal actions, and damage to the company's reputation can arise if such events occur. Vericel must maintain rigorous safety standards and effectively communicate the benefits and risks of its products.

Vericel Revenue by Segment

  • 3 years

  • 5 years

  • Max

Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Vericel Revenue by Segment

Segmente2023202220192018
Total MACI implants and kits164.8 M USD---
M A C I Implants And Kits-131.97 M USD--
Epicel31.57 M USD31.73 M USD26.23 M USD23.12 M USD
Implants--1.53 M USD25.1 M USD
MACI implants and kits4.92 M USD3.5 M USD--
Biopsy kits-2.09 M USD2.24 M USD-
Biopsy kits - direct bill2.09 M USD---
Biopsy Kits---2 M USD
Other revenue----
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Vericel Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Vericel historical P/E ratio, EBIT multiple, and P/S ratio

LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Vericel shares outstanding

The number of shares was Vericel in 2023 — This indicates how many shares 47.59 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Vericel earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Vericel's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Vericel’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Vericel's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Vericel stock splits

In Vericel's history, there have been no stock splits.
LIMITED TIME OFFER

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Vericel.

Vericel latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2024-0.05 -0.02  (59.6 %)2024 Q3
6/30/2024-0.09 -0.1  (-16.01 %)2024 Q2
3/31/2024-0.11 -0.08  (28.57 %)2024 Q1
12/31/20230.17 0.26  (49.68 %)2023 Q4
9/30/2023-0.12 -0.08  (35.79 %)2023 Q3
6/30/2023-0.15 -0.11  (28.94 %)2023 Q2
3/31/2023-0.16 -0.16  (-2.37 %)2023 Q1
12/31/20220.04 0.12  (232.41 %)2022 Q4
9/30/2022-0.1 -0.14  (-34.62 %)2022 Q3
6/30/2022-0.12 -0.19  (-52.49 %)2022 Q2
1
2
3
4
5
...
6

Eulerpool ESG Scorecard© for the Vericel stock

Eulerpool World ESG Rating (EESG©)

44/ 100

🌱 Environment

16

👫 Social

43

🏛️ Governance

72

Environment

Scope 1 - Direct Emissions
Scope 2 - Indirect emissions from purchased energy
Scope 3 - Indirect emissions within the value chain
Total CO₂ emissions
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees37
Percentage of women in management
Percentage of Asian employees
Share of Asian management
Percentage of Hispanic/Latino employees
Hispano/Latino Management share
Percentage of Black employees
Black Management Share
Percentage of white employees68
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Vericel shareholders

%
Name
Stocks
Change
Date
14.88756 % BlackRock Institutional Trust Company, N.A.7,348,50267,1806/30/2024
8.94790 % Brown Capital Management, LLC4,416,684-534,2596/30/2024
6.95793 % The Vanguard Group, Inc.3,434,43529,7636/30/2024
4.92212 % State Street Global Advisors (US)2,429,558-55,2279/30/2024
4.71156 % Fidelity Management & Research Company LLC2,325,624241,7656/30/2024
4.20529 % Conestoga Capital Advisors, LLC2,075,73034,3609/30/2024
2.98293 % Invesco Advisers, Inc.1,472,3731,309,8756/30/2024
2.61694 % Congress Asset Management Company, LLP1,291,720351,5509/30/2024
2.54409 % GW&K Investment Management, LLC1,255,76230,0866/30/2024
2.31856 % Geode Capital Management, L.L.C.1,144,44080,4956/30/2024
1
2
3
4
5
...
10

Vericel Executives and Management Board

Mr. Dominick Colangelo

(59)
Vericel President, Chief Executive Officer, Director (since 2013)
Compensation 8.71 M

Mr. Michael Halpin

(61)
Vericel Chief Operating Officer
Compensation 3.1 M

Mr. Joseph Mara

(48)
Vericel Chief Financial Officer
Compensation 2.39 M

Dr. Jonathan Hopper

(60)
Vericel Chief Medical Officer
Compensation 2.06 M

Mr. Sean Flynn

(49)
Vericel Senior Vice President, General Counsel, Secretary
Compensation 2.04 M
1
2
3

Vericel Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
IQVIA Holdings Stock
IQVIA Holdings
SupplierCustomer0,760,790,810,710,460,69
Omnicom Stock
Omnicom
SupplierCustomer0,700,540,620,07-0,200,74
Envista Holdings Stock
Envista Holdings
SupplierCustomer0,62-0,430,680,39-0,270,75
MediWound Stock
MediWound
SupplierCustomer0,160,440,570,460,920,36
1

Most common questions regarding Vericel

What values and corporate philosophy does Vericel represent?

Vericel Corp represents a commitment to improving patients' lives through innovative cell therapy solutions. The company seeks to develop and commercialize therapies that restore or regenerate damaged tissues. Vericel Corp espouses integrity, excellence, and patient focus as its core values. With a passion for scientific advancement and dedication to delivering transformative treatments, Vericel Corp strives to positively impact the lives of patients and healthcare providers. By leveraging cutting-edge research and technology, the company aims to address significant unmet medical needs and improve outcomes in areas such as orthopedic and cardiac care.

In which countries and regions is Vericel primarily present?

Vericel Corp is primarily present in the United States.

What significant milestones has the company Vericel achieved?

Vericel Corp has achieved several significant milestones since its inception. The company has successfully developed and gained FDA approval for two pioneering treatments, MACI and Epicel. MACI is a breakthrough therapy for the repair of adult knee cartilage defects, offering long-lasting pain relief and improved function for patients. On the other hand, Epicel is an advanced treatment for severe burns, providing a permanent solution for covering large burn areas. Vericel Corp has also expanded its presence in the market through strategic collaborations and partnerships, strengthening its position as a leading innovator in the regenerative medicine field.

What is the history and background of the company Vericel?

Vericel Corp, established in 1989, is a leading biopharmaceutical company specializing in the development and commercialization of innovative cell therapies. With headquarters in Cambridge, Massachusetts, Vericel focuses on delivering transformative therapies to patients with serious medical conditions. The company initially operated under the name Aastrom Biosciences and rebranded as Vericel in 2014. Over the years, Vericel Corp has made significant advancements in the field of regenerative medicine, particularly in utilizing a patient's own cells to create personalized therapies. With a strong commitment to research, development, and clinical trials, Vericel continues to make strides in providing groundbreaking treatments to improve patients' lives.

Who are the main competitors of Vericel in the market?

The main competitors of Vericel Corp in the market are companies like NuVasive, Organogenesis Holdings Inc., and Athersys Inc. These companies operate in the same industry and offer similar products and services. However, Vericel Corp differentiates itself through its innovative technologies, strong research and development capabilities, and its focus on regenerative medicine solutions. With its unique product portfolio and market expertise, Vericel Corp remains well-positioned in the market despite competition from these key rivals.

In which industries is Vericel primarily active?

Vericel Corp is primarily active in the biotechnology industry.

What is the business model of Vericel?

The business model of Vericel Corp revolves around the development and commercialization of innovative cell therapy products. Vericel focuses on using advanced cellular and regenerative medicine technologies to provide treatments for patients with severe diseases and conditions. The company's portfolio includes products such as MACI, an autologous cellularized scaffold for the repair of symptomatic, full-thickness cartilage defects of the knee, and Epicel, a permanent skin replacement for patients with deep dermal or full-thickness burns. Vericel Corp aims to address unmet medical needs and improve the lives of patients through its cutting-edge cell therapy solutions.

What is the P/E ratio of Vericel 2024?

The Vericel P/E ratio is 430.67.

What is the P/S ratio of Vericel 2024?

The Vericel P/S ratio is 10.97.

What is the Quality Investing of Vericel?

The Quality Investing for Vericel is 2/10.

What is the revenue of Vericel 2024?

The expected Vericel revenue is 244.56 M USD.

How high is the profit of Vericel 2024?

The expected Vericel profit is 6.23 M USD.

What is the business model of Vericel

Vericel Corp is a leading biopharmaceutical company specializing in the development, manufacturing, and marketing of products for the regeneration of human tissue. The company focuses on researching and developing top-tier therapeutic options for critical medical needs that have previously been unmet. One important area of the company is the extraction, cultivation, and processing of autologous cells and tissues. Vericel's products are derived from the patient's own tissue, making them particularly safe and suitable for use. The company offers innovative treatment options based on the use of autologous cells and tissues obtained from the skin, bone marrow, adipose tissue, and other tissues. The flagship product, MACI, is a cell transplantation product used to treat knee cartilage damage in adult patients. MACI is unique in that the process of autologous tissue engineering is employed in its production, facilitating the regeneration of the patient's cartilage. Vericel's second area of focus is the treatment of patients with severe burns. This area includes the use of the product Epicel, which is used to treat large burn wounds. Epicel is created by applying an autologous keratinocyte cell suspension film to the wound, resulting in rapid and effective wound healing. Vericel also has an extensive clinical pipeline focused on tissue regeneration and the treatment of degenerative diseases. The company is working on developing autologous cell therapies to improve outcomes for patients with myocardial infarction and various neurological conditions such as ALS, Huntington's disease, and Parkinson's disease. To sustain and expand its business, Vericel collaborates with a variety of partners including hospitals, clinics, and practices. The company also has a strong marketing initiative to raise awareness of its innovative products and their medical benefits. In conclusion, Vericel Corp's business model is based on the development of novel and innovative therapeutic options using autologous cells and tissues. These therapies have great potential to aid patients with previously unmet medical needs. Through a strong marketing initiative, partnerships, and an extensive clinical pipeline, the company strives for steady growth and success.

What is the Vericel dividend?

Vericel pays a dividend of 0 USD distributed over payouts per year.

How often does Vericel pay dividends?

The dividend cannot currently be calculated for Vericel or the company does not pay out a dividend.

What is the Vericel ISIN?

The ISIN of Vericel is US92346J1088.

What is the Vericel WKN?

The WKN of Vericel is A12FU4.

What is the Vericel ticker?

The ticker of Vericel is VCEL.

How much dividend does Vericel pay?

Over the past 12 months, Vericel paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Vericel is expected to pay a dividend of 0 USD.

What is the dividend yield of Vericel?

The current dividend yield of Vericel is .

When does Vericel pay dividends?

Vericel pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Vericel?

Vericel paid dividends every year for the past 0 years.

What is the dividend of Vericel?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Vericel located?

Vericel is assigned to the 'Health' sector.

Wann musste ich die Aktien von Vericel kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Vericel from 12/20/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 12/20/2024.

When did Vericel pay the last dividend?

The last dividend was paid out on 12/20/2024.

What was the dividend of Vericel in the year 2023?

In the year 2023, Vericel distributed 0 USD as dividends.

In which currency does Vericel pay out the dividend?

The dividends of Vericel are distributed in USD.

All fundamentals about Vericel

Our stock analysis for Vericel Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Vericel Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.